Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trial...
Viracta Therapeutics reported revenue of $0 for fiscal year 2023, and net income of -$51.06 million. In Q3 2024 (the quarter ended September 30, 2024) revenue was $0. Its market capitalization was $388,698 as of December 30, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of December 30, 2025.
No profile data available.